Uber anti-epileptic new drug padsevonil 2b clinical failure!

UCB recently released the results of the study of the new anti-epileptic drug padsevonil IIb (NCT03373383)The results showed that, during the 12-week maintenance period, padsevonil did not achieve a statistically significant improvement in the two major endpoints of the study compared to placeboThis is a randomized, double-blind, placebo-controlled, dose-discovery study designed to assess the efficacy and safety of padsevonil as an adjunct therapy drug for the treatment of lesions in adult patients with drug-resistant epilepsyThe study group was a drug-resistant type of epilepsy patient who had used four or more anti-epileptic drugs but whose condition was not controlled and who were currently treating 1-3 anti-epileptic drugsIn the study, 515 cases were randomly divided into five groups and received different doses of padsevonil (n-414) or placeboThe main endpoint was the change in the relative baseline frequency of the frequency of the meta-lesions during the 12-week maintenance period, and the proportion of respondents who decreased by 75% relative to the baselinestudies, padsevonil was well tolerated and had safety consistent with earlier studiesepilepsy is a major symptom of a variety of chronic brain diseases and is the fourth most common neurological disease in the world, affecting about 65 million peopleEpilepsy can occur for anyone, which can occur in any age, race, or gender population, with profound physical, psychological and social consequences and a significant impact on an individual's quality of lifeCurrently, the purpose of epilepsy treatment is to enable patients to live as normal a life as possible, without seizures, with little or no side effects"Up to one-third of people with pciepilepsons are unable to effectively control seizures with the anti-epileptic drugs currently available, which is an unmet and significant medical need," said Iris Loew Friedrich, chief medical officer of theUCBDisappointingly, padsevonil did not significantly improve seizure control in these patientsWe will conduct further data analysis to better understand the results and their impact on the global epilepsy communityPadsevonil Chemical Structure (Photo: medchemexpress.cn)Padsevonil is a two-acting anti-epileptic drug whose mechanism is specifically targeted for interaction between the synaptic pre-target and the synaptic post-targetPrior to the synapse, padsevonil binds to three subtypes (SV2A, SV2B, SV2C) with high affinity in synaptic cystic protein 2; Previous Phase II proof-of-concept studies have shown that padsevonil treatment may be associated with a clinically significant reduction in the frequency of seizures, and suggest acceptable tolerance and safety ARISE is the first of two well-controlled studies, and UCB is currently evaluating the impact of the ARISE study on the second ongoing UCB0092 (DUET) study reference source: UCB provides an update on Phase 2b padsevonil safety and efficacy in epilepsy (ARISE)